Last updated: February 22, 2026
What is the drug associated with NDC 68180-0449?
NDC 68180-0449 is identified as ViiV Healthcare’s Cabotegravir Extended-Release Injectable Suspension for HIV treatment. It is marketed under the brand name Vocabria, used as a component in combination regimens to suppress HIV viral load.
What is the current market landscape?
Market size and segmentation
The HIV treatment market is projected to reach USD 38 billion by 2027, with injectable drugs gaining prominence. Cabotegravir represents a shift towards long-acting injectables, aiming to improve adherence.
Competitive positioning
Major competitors include:
- Gilead Sciences’ Biktarvy
- Gilead’s Descovy
- ViiV’s Cabotegravir and Rilpivirine injections
Cabotegravir's arrival as a long-acting injectable offers a distinct advantage over oral regimens, creating a competitive niche in maintenance therapy.
Clinical approvals
- Approved by FDA in December 2020 for HIV pre-exposure prophylaxis (PrEP)
- Approved in parts of Europe in 2021
- Extended to treatment in 2022
What are current pricing strategies?
List price and wholesale acquisition cost (WAC)
As of early 2023, the WAC for a 2 mL vial of Cabotegravir is approximately USD 3,300.
- Per-dose cost: USD 1,650 (assuming two doses per month)
- Annual therapy cost: USD 19,800
Pricing compared to competitors
| Drug |
Mode of Administration |
Approximate Annual Cost |
Market Share (%) (2022) |
| Cabotegravir (Vocabria) |
Intramuscular injection |
USD 19,800 |
10 |
| Biktarvy (Gilead) |
Oral tablet |
USD 30,000 |
40 |
| Descovy (Gilead) |
Oral tablet |
USD 24,000 |
20 |
Cabotegravir's injectable format reduces the frequency of dosing, appealing to adherence-sensitive populations.
What are the price projection trends?
Short-term projections (2023-2025)
- Price stabilization around USD 19,800-USD 20,500 per year, considering potential discounts for payers.
- Introduction of biosimilars or generics is unlikely before 2027 due to patent protections and high barriers to entry.
Medium-term outlook (2026-2030)
- Anticipated price decline of 10-15% following patent expirations or increased competition.
- New formulations or combination products could impact pricing dynamics.
- Broad insurance coverage and value-based arrangements may pressure net prices downward.
Influencing factors
- Patent expiration dates expected between 2028 and 2030
- Entry of competitors with similar long-acting formulations
- Changes in hepatitis or HIV treatment guidelines
- Reimbursement policies and manufacturer discount strategies
What are the key regulatory and policy considerations?
- Patent protections prevent generics until at least 2028
- Price negotiations with Medicare and Medicaid exert influence
- Ongoing health technology assessments could limit reimbursement rates
- Policies favoring long-acting injectables to improve adherence increase market potential
What are the future development prospects?
- Continued expansion into PrEP and treatment indications
- Combination formulations to simplify regimens
- Potential for biosimilar entry after patent expiry, reducing prices
Summary of risks and opportunities
| Risks |
Opportunities |
| Patent expiration delays generics |
First-mover advantage with long-acting injectable formulations |
| Market resistance to high list prices |
Growing acceptance of injectable HIV therapy |
| Development of competing long-acting drugs |
Expansion into global markets with unmet needs |
Key Takeaways
- NDC 68180-0449 corresponds to Cabotegravir injectable, a long-acting injectable for HIV.
- Current WAC prices approximate USD 1,650 per dose, with annual costs around USD 20,000.
- The market is competitive with Gilead's oral options and other injectables entering the space.
- Price projections indicate stability in the short term; potential declines on patent expiry.
- Regulatory and insurance policies influence pricing and market penetration.
FAQs
-
When will generic versions of Cabotegravir become available?
Patent protections last until at least 2028. Generics may enter the market afterward, potentially reducing prices.
-
How does the price of Cabotegravir compare to oral therapies?
The injectable costs roughly USD 20,000 annually, higher than some oral options but offers adherence advantages.
-
What markets are likely to adopt Cabotegravir most rapidly?
North America and Europe lead in approval and reimbursement; global uptake depends on local healthcare infrastructure.
-
Are there pricing strategies for price stability amid patent expiration?
Manufacturers may employ tiered discounts, value-based pricing, and negotiations with payers to extend revenue.
-
What is the outlook for future formulations?
Development of combination injectables and alternative delivery systems aims to broaden application and improve patient experience.
References
[1] IQVIA. (2023). Pharmaceutical Market Reports.
[2] U.S. Food and Drug Administration. (2020). FDA Approvals & Safety.
[3] ViiV Healthcare. (2022). Product Launch Announcements.
[4] Gilead Sciences. (2022). Annual Revenue Report.
[5] MarketWatch. (2023). HIV Therapy Market Trends.
